ArticleCancer biology & medicine2025
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC.
Article in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical evaluation of low-dose radiation therapy for immunotherapy resistance in advanced non-small cell lung cancer.Translational cancer research · 2026Article
- Deciphering the Molecular Basis: Integrative Multi-Method Analysis of Bioactive Constituents and Their Anti-Lung Cancer Mechanisms in Clinical Traditional Chinese Medicine Formulations.Chemistry & biodiversity · 2026Article
- Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients.ACS pharmacology & translational science · 2026Review
- Research progress and trends on DNA methylation research in non-small cell lung cancer: a bibliometric analysis.Journal of thoracic disease · 2026Article
- Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study.JTO clinical and research reports · 2026Article
- Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026Review
- Alterations in peripheral blood inflammatory mediators, vascular endothelial growth factor, and serum tumor markers in advanced non-small cell lung cancer patients treated with bevacizumab combined with chemotherapy.American journal of translational research · 2026Article
- Cost-effectiveness analysis of combined immunotherapy regimens for non-squamous non-small lung cancer after tyrosine kinase inhibitors resistance.Frontiers in public health · 2026Article
- Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study.BMC cancer · 2025Article
- Clinical study of aumolertinib versus osimertinib in the treatment of EGFR-mutated advanced non-small cell lung cancer.Discover oncology · 2025Article
- Primary endobronchial epithelial-myoepithelial carcinoma: A case report and literature review.Experimental and therapeutic medicine · 2025Article
- Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Dissecting the intratumoral microbiome landscape in lung cancer.Frontiers in immunology · 2025Review
- Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China.Frontiers in immunology · 2025Article
- Efficacy and safety of EGFR-TKI for EGFR-mutated NSCLC: systematic review and network meta-analysis.International journal of clinical and experimental pathology · 2025Review
- Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.